Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

First International Summit on Interventional Pharmacoeconomics

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David A. Hyman, MD, JD, on Inclusive Shared Savings

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

May

Today In Oncology

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Sonrotoclax Receives Accelerated Approval in Relapsed or Refractory MCL

FDA Approves Combination Regimen for Newly Diagnosed AML

Study Examines Genetic Testing to Inform Follow-up Care for Cancer Survivors

Global Review Shows Impact of Exposure to Air Pollution on Cancer Risk and Mortality

Addition of Toripalimab to Perioperative Chemotherapy in Locally Advanced Gastric or Gastroesophageal Junction Cancer